Surface Oncology is a clinical-stage immuno-oncology company focused on using its knowledge of the biological pathways crucial to the immunosuppressive tumor microenvironment (TME) for the development of cancer therapies. NZV930 and SRF617 are antibodies inhibiting cluster of differentiation, or CD, 73 and CD39, respectively, and illustrate how Co.'s knowledge of TME biology can be used across programs. SRF388 is an antibody targeting interleukin 27, or IL-27, an immunosuppressive cytokine, or protein secreted by cells, in the TME that is overexpressed in certain cancers, including hepatocellular and renal cell carcinoma. SRF813 is an antibody targeting CD112R. The SURF stock yearly return is shown above.
The yearly return on the SURF stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SURF annual return calculation with any dividends reinvested as applicable (on ex-dates).
|